대한신장학회

논문분류	춘계학술대회 초록집
제목	Analysis of 300 ABO incompatible kidney transplantations in a single center
저자	Eun Jeong Ko, Byung Ha Chung, Cheol Whee Park, Yong-Soo Kim, Chul Woo Yang
출판정보	2021; 2021(1):
키워드
초록	Objective: This is a retrospective, observational study using data extracted from medical records. A total of 300 consecutive patients who underwent ABOi-KT at our institution from May 2009 to Nov 2020 were included in this study. Methods: From a Kaplan-Meier analysis, overall patient survival after ABOi KT at 1, 3, 5 years were 98.3%, 97.6%, and 97.0%, respectively. The death censored graft survival rates after ABOi KT at 1, 3, and 5 years were 97.2 %, 91.4%, and 86.4%, respectively. Our analysis suggested that overall patient survival, death-censored graft survival, and rejection free graft survival in ABOi KT showed no significant differences in comparison with ABO-compatible KT. (p=0.34, p=0.41, and p=0.88 for each) Interestingly, BKViremia was more commonly observed in ABOi KT compared to ABOc KT (17.0% vs. 9.6%, p=0.005). Furthermore, in multivariable analysis, ABO-incompatibility itself increased the risk of BKViremia significantly compared to control. (HR=1.40, p=0.03) Results: The outcomes of ABOi KTs continually improved during the study period, while the annual number of KTs increased. ABO incompatible KT can be performed safely with successful graft outcomes. Conclusions: Objective: Kidney transplant (KT) is the optimal renal replacement therapy for patients with end-stage renal disease (ESRD). However, the demand for kidneys continues to exceed the supply. To overcome this problem, efforts to extend the donor pool by including ABO-incompatible kidney transplantation (ABOi-KT) has been increased. The aim of this article was to retrospectively review data on recipients, donor profiles, and clinical outcome in 300 cases of ABOi compatible KT in a single center. Methods: This is a retrospective, observational study using data extracted from medical records. A total of 300 consecutive patients who underwent ABOi-KT at our institution from May 2009 to Nov 2020 were included in this study. Results: From a Kaplan-Meier analysis, overall patient survival after ABOi KT at 1, 3, 5 years were 98.3%, 97.6%, and 97.0%, respectively. The death censored graft survival rates after ABOi KT at 1, 3, and 5 years were 97.2 %, 91.4%, and 86.4%, respectively. Our analysis suggested that overall patient survival, death-censored graft survival, and rejection free graft survival in ABOi KT showed no significant differences in comparison with ABO-compatible KT. (p=0.34, p=0.41, and p=0.88 for each) Interestingly, BKViremia was more commonly observed in ABOi KT compared to ABOc KT (17.0% vs. 9.6%, p=0.005). Furthermore, in multivariable analysis, ABO-incompatibility itself increased the risk of BKViremia significantly compared to control. (HR=1.40, p=0.03) Conclusions: The outcomes of ABOi KTs continually improved during the study period, while the annual number of KTs increased. ABO incompatible KT can be performed safely with successful graft outcomes.
원문(PDF)	PDF 원문보기

간행물 검색

대한신장학회 회원관리 규정